Displaying 1 - 10 of 1665 Results
Broker-dealers that recommend or sell private placements have additional requirements under FINRA and SEC rules. These requirements include: Filing certain offering documents Ensuring the suitability of any investments they recommend Filing Requirements Two FINRA rules require firms to file certain offering documents and information about the issuer, the offering terms, and the firms selling
Summary In this Notice, FINRA reminds members of their obligations when selling private placements (i.e., unregistered offerings sold pursuant to the Regulation D safe harbors under Sections 3 and 4 of the Securities Act of 1933 (Securities Act)). In Regulatory Notice 10-22 (Obligation of Broker-Dealers to Conduct Reasonable Investigations in Regulation D Offerings), FINRA reminded members of
The Reasonable Diligence for Private Placements section of the 2018 Report on Exam Findings informs member firms’ compliance programs by describing recent findings and observations from FINRA’s examinations, and, in certain cases, also providing a summary of effective practices.
Frequently asked questions about private placements.
Washington, D.C. - The Financial Industry Regulatory Authority (FINRA) today announced the publication of guidance for FINRA-registered firms about their obligations regarding customer suitability, disclosures and other requirements for selling private placements to customers, an area where recent examinations and enforcement actions have revealed a significant lack of regulatory compliance.
The Corporate Financing Department assists FINRA-regulated firms in complying with FINRA rules and federal securities laws by reviewing documents related to firms' capital-raising activities and arrangements. These services provide protections to investors and issuers by regulating underwriting terms and arrangements and addressing conflicts of interest when underwriters are affiliated with
Investors should be wary of schemes on the internet and social media claiming to raise money for companies promising new health care products that detect, treat, or cure COVID-19. While some could be legitimate, many will ring hollow, leaving investors with nothing but broken promises and empty pockets.
FINRA Continues Nationwide Initiative Investigating Broker-Dealers Engaged in Private Placements